ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > 展示会 > Addressing Challenges in Antibody-Drug Conjugate Development
  1. Addressing Challenges in Antibody-Drug Conjugate Development

    1. September 12, 2024 12:00 CET
    2. Online
    3. ACROBiosystems
    Click the button to enter our raffle.
  2. Guest Speaker

    Hengshuo Liu

    Dr. Hengshuo Liu

    Technical Sales Supervisor

    Topic:

    Addressing Challenges in Antibody-Drug Conjugate Development

    Introduction

    Antibody-drug conjugates (ADCs) are a cutting-edge class of targeted cancer therapies that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, allowing for the precise delivery of chemotherapy to cancer cells while minimizing damage to healthy tissue. Despite their promise, the development of ADCs faces significant challenges, including optimizing the stability of the conjugate, ensuring effective drug release at the target site, and managing potential off-target effects. This webinar will explore the latest advancements in ADC technology and strategies to overcome these critical hurdles in drug development.

    Organisers

    ACRO

    ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Our mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. We supply life science tools designed to be used in discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, we deliver solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. We empower scientists and engineers dedicated towards innovation to simplify and accelerate the development of new, better, and more affordable medicine.

New & Hot Products


This web search service is supported by Google Inc.

totopphone